Cargando…
Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment
Purpose. To present cases with retinopathy of prematurity (ROP), who were treated with intravitreal injection of ranibizumab (IVR) and had unpredictable asymmetric outcomes. Methods. A retrospective review was performed in infants with type 1 ROP and had bilateral IVR (0.25 mg/0.025 mL) as initial t...
Autores principales: | Huang, Qiujing, Zhang, Qi, Xu, Yu, Ji, Xunda, Fei, Ping, Peng, Jie, Li, Yi-an, Zhao, Peiquan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390587/ https://www.ncbi.nlm.nih.gov/pubmed/28465833 http://dx.doi.org/10.1155/2017/1741386 |
Ejemplares similares
-
Combination of Intravitreal Injection of Ranibizumab and Photocoagulation for the Treatment of Aggressive Posterior Retinopathy of Prematurity with Vitreous Hemorrhage
por: Xu, Yu, et al.
Publicado: (2016) -
Intravitreal Ranibizumab for Aggressive Posterior Retinopathy of Prematurity
por: Li, Xiu-Juan, et al.
Publicado: (2016) -
Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40 weeks post menstrual age: a retrospective case series study
por: Lyu, Jiao, et al.
Publicado: (2019) -
Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity
por: Chen, Xuting, et al.
Publicado: (2019) -
Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity
por: Hoppe, Charis, et al.
Publicado: (2022)